LAUSR

Telmisartan, an angiotensin II receptor blocker, and azelnidipine, a dihydropyridine calcium channel blocker, are often co‐prescribed for the effective management of hypertension. The development of accurate and efficient analytical methods is crucial for ensuring the quality control of these combination formulations. This study presents a rapid and reliable reversed‐phase ultra‐performance liquid chromatography (RP‐UPLC) assay for the simultaneous determination of telmisartan and azelnidipine in pharmaceutical formulations. Efficient chromatographic separation was achieved on an ACQUITY BEH C18 column (100 mm × 2.1 mm, 3 µm) using an isocratic mobile phase of pH 4.0 ammonium acetate buffer and acetonitrile (75:25% v/v) at a flow rate of 0.5 mL/min. Detection was performed at 260 nm, with telmisartan and azelnidipine eluting at 1.833 and 3.583 min, respectively. The method demonstrated good efficiency and minimal tailing (<1.5). Validation parameters, including accuracy, precision, linearity, specificity, and sensitivity, were determined according to International Council for Harmonisation guidelines. Calibration curves for both analytes exhibited excellent linearity (correlation coefficients > 0.999) over a concentration range of 50–150%. Recoveries from tablet dosage forms ranged from 98.0% to 102.0%, with assay values falling within the prescribed range. This validated that reversed‐phase ultra‐performance liquid chromatography assay offers a high‐throughput approach suitable for routine quality control analysis of telmisartan and azelnidipine in pharmaceutical formulations.